Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px

Document › Details

Univercells S.A.. (3/15/21). "Press Release: Univercells, Univercells Technologies and Gamma Biosciences Announce Mathias Garny as New CEO of Univercells Technologies". Brussels.

	Organisation	Univercells Technologies S.A.
	Group	Univercells (Group)
	Organisation 2	Gamma Biosciences (a life sciences tools platform of KKR)
	Group	KKR (Kohlberg Kravis Roberts) (Group)
	Product	contract manufacturing (biologicals)
	Product 2	private equity
	Person	Garny, Mathias (Univercells 202005 CCO + General Manager at Univercells Technologies)
	Person 2	Gunnison, Matthew t. (Matt) (KKR 202104 President of Gamma Biosciences before GE Healthcare before Sidley Austin LLP)

Mathias Garny has been appointed as the Chief Executive Officer of Univercells Technologies, a Univercells company and global provider of next-generation bioprocess technologies.

Univercells S.A. (“Univercells”), Univercells Technologies (the “Company”), and Gamma Biosciences (“Gamma”) are pleased to announce that effective March 15, 2021, Mathias Garny has been appointed as the Chief Executive Officer of Univercells Technologies, a Univercells company and global provider of next-generation bioprocess technologies. The appointment of Mr. Garny will usher a new era for the Company with a focus on commercializing the company’s product portfolio and new technology developments to further expand market reach and success.

Already acting as General Manager, Mr. Garny has been responsible for overseeing the Company’s operations and leading the strategy development and implementation. Under his leadership, the Company introduced new products and expanded international operations.

Mr. Garny first joined Univercells in 2015 as Chief Financial Officer to define the financial strategy and spearhead fundraising activities. As the company grew, he transitioned to Chief Commercial Officer in 2017, playing a key role in Univercells’ development and commercialization efforts of the technology portfolio, including the scale-X™ single-use bioreactor range and the NevoLine™ biomanufacturing platform.

In February 2020, Gamma Biosciences, a global life sciences company backed by the investment firm KKR, invested € 50 million to launch Univercells Technologies following its carve-out from Univercells and accelerate the industrialization and commercialization of its manufacturing technologies. “Mathias has demonstrated exceptional leadership as we’ve sought to aggressively grow the Univercells Technologies offer as part of the Gamma platform and across the industry. In this new role as CEO, he will further advance the company’s mission to make biologics and gene therapies more affordable through its next generation bioprocessing and manufacturing technologies,” commented Matt Gunnison, President of Gamma Biosciences.

Hugues Bultot, CEO of Univercells commented: “The Board and I are delighted to appoint Mathias as the new CEO. His background in business strategy, operations, business planning, and fundraising are key assets that will help to ensure the sustained growth of Univercells Technologies. I am confident that Mathias will bring Univercells Technologies into the next phase of growth and see his appointment as an example of the internal career progression available in our companies.”

Mathias Garny addressed his new role, adding: “Univercells Technologies is a fantastic success story with a deep Belgian anchorage. We are built on strong values and entrepreneurial spirit and have grown a diverse pool of driven, forward-focused talents. I am honored to be trusted with the task of taking the Company through the next stage of strategic development and growth.”

Record changed: 2023-06-05